Skip to content

Evaluating the Prognostic Impact of Anti-ß1AR Antibodies and Anti-L-CaC Antibodies in Patients with Dilated Cardiomyopathy

DCM antimyocardial antibody diagnostic kit study--Evaluating the Prognostic Impact of Anti-ß1AR Antibodies and Anti-L-CaC Antibodies in Patients with Dilated Cardiomyopathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093837
Enrollment
Unknown
Registered
2024-12-12
Start date
2024-12-15
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dilated cardiomyopathy

Interventions

cases group:None

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age 18-75, any gender; 2.Diagnosed with dilated cardiomyopathy; 3.Subjects or their legal guardians are fully informed of the nature and risks of the study, participate voluntarily, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Serious uncontrolled infection at enrolment ('uncontrolled' is defined as signs and symptoms of infection that persist without improvement despite antimicrobial or other treatment); 2.Uncontrolled active bleeding at enrollment; 3.Pregnancy or breastfeeding; 4.Combination of serious diseases affecting survival, such as tumors, with a life expectancy of less than one year; 5.Previous heart transplant or implantation of a cardiac assist device; 6.Patients with poor compliance who are unable to complete the full course of the study; 7.Other conditions (e.g., overstimulation, sensitivity, cognitive impairment, mental illness, or substance abuse/addiction) that, in the judgment of the investigator, may increase the risk to the subject or interfere with the clinical study and judgment of the results.

Design outcomes

Secondary

MeasureTime frame
All-cause death, heart transplant, heart failure rehospitalization, or sudden death;

Primary

MeasureTime frame
Composite Endpoint of All-Cause Death, Heart Transplantation, and Rehospitalization for Heart Failure;

Countries

China

Contacts

Public ContactJing Yuan

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

yhelen13@aliyun.com+86 27 85726009

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026